Home / Industries / How Much Does It Cost to Start an Opioid Treatment Program?

How Much Does It Cost to Start an Opioid Treatment Program?

Reviewed by Muhammad Tayyab Shabbir · Last updated 12 October 2026

The government fees are trivial and the real cost is elsewhere. 42 CFR 8.11 prescribes no fee for SAMHSA certification of an opioid treatment program, and DEA registration is $296 for a one-year registration period. Adding the only other government fee we could verify against a primary source, Tennessee's Certificate of Need filing fee, the total verifiable published government cost of the gate chain in year one is $296 in a state with no CON requirement, or $3,296 to $45,296 in Tennessee. That is a fee total, not a startup cost. What actually consumes capital is the pre-revenue carry while you clear a fixed sequence of gates, state licensure, accreditation, SAMHSA certification, DEA registration, and a Certificate of Need in states that require one, and none of the large lines (facility, build-out, security, staffing, working capital) has an authoritative published figure we were able to source.

We do not publish a headline "total startup cost" range, because the items that would dominate it are not published anywhere we could verify. Every figure below either carries a named source with a retrieval date, or is labelled in the visible text as our own estimate or assumption. The one filed whole-project estimate we found is in the table as a single data point, not a range.

Cost at a glance: what each gate actually costs

Read that total for what it is. It sums only the government fees in this table that have a verifiable published dollar amount. It excludes accreditation fees, state license fees, the DEA security build, the facility, build-out, equipment, staffing and every month of pre-revenue carry, because none of those has a published figure we could source. If someone quotes you an all-in startup number for an OTP, ask them to show you where each line came from.

What drives the cost of opening a methadone clinic?

Four things.

Pre-revenue carry. You cannot dispense a dose until the whole gate chain is complete: 42 CFR 8.11(e)(6) requires that OTPs "must be registered by the DEA before administering or dispensing MOUD." Rent, clinical payroll and compliance costs run from lease signature, so every month of delay is full fixed cost against zero revenue.

Certificate of Need, where it applies. A CON adds a separate application and review, and in Tennessee a filing fee that scales with your capital expenditure up to $45,000, before you can open. On the one Tennessee filing we read, the fee works out at the $3,000 minimum (worked example below).

The DEA Schedule II security build. Not a generic "equipment" line. Methadone is a Schedule II controlled substance, so 21 CFR 1301.72(a) applies. It requires storage in one of three secured areas. "Where small quantities permit," a safe or steel cabinet meeting "30 man-minutes against surreptitious entry, 10 man-minutes against forced entry, 20 man-hours against lock manipulation, and 20 man-hours against radiological techniques", bolted or cemented down if it weighs less than 750 pounds, and alarmed where the quantities and type of substances stored make an alarm necessary. Otherwise a vault: for one built after 1 September 1971, walls, floors and ceilings "of at least 8 inches of reinforced concrete or other substantial masonry, reinforced vertically and horizontally with 1/2-inch steel rods tied 6 inches on center," a door and frame meeting the same man-minute specification, a perimeter alarm signalling a central station protection company, a responding police agency or a 24-hour control station operated by the registrant, contact switches on the door, and an interior detection system. Design this before the build-out, not after.

Payer mix. Below: across the two payer rate sets we were able to source, annual revenue per patient differs by a factor of roughly 2.6 for the same number of patients on methadone.

What is the OTP licensing pathway, step by step?

The federal steps below are fixed by regulation. Where a state sits in the order is not, so confirm your own sequence with your State Opioid Treatment Authority in writing.

1. Certificate of Need, where required. Whether CON approval must precede state licensure, and how CON interacts with site control, varies by state: we could not source a rule that holds nationally, so do not assume the order. Ask your state health planning agency before you commit to a site.
2. State licensure and SOTA engagement. 42 CFR 8.2 defines the State Opioid Treatment Authority as "the agency designated by the Governor of a State, or other appropriate official designated by the Governor, to exercise the responsibility and authority within the State or Territory for governing the treatment of OUD with MOUD in OTPs." 42 CFR 8.11(e)(1) requires that OTPs "shall comply with all pertinent Federal and State laws and regulations."
3. Apply to an Accreditation Body. Under 42 CFR 8.11(a)(2) certification requires the OTP to be "the subject of a current, valid accreditation by an Accreditation Body or other entity designated by the Secretary". SAMHSA's website refused automated retrieval on 11 October 2026, so we could not confirm which bodies it currently approves, including the two accreditors in the cost table: check with SAMHSA before you apply.
4. File Form SMA-162 with SAMHSA for provisional certification. Under 42 CFR 8.11(d) a new OTP that has applied for accreditation is eligible for provisional certification for up to one year. The filing must identify the accrediting body, the date of application, the dates of any accreditation surveys and the expected schedule for completing accreditation: this is what lets you open before accreditation finishes.
5. SAMHSA consults your state authority. Under 42 CFR 8.11(c)(1) the Secretary may grant certification "after consultation with the appropriate State authority regarding the qualifications of the applicant". The regulation does not state what weight a state objection carries; our advice is to treat active SOTA support as a practical precondition rather than a courtesy.
6. SAMHSA notifies DEA within 5 days of a final determination that the OTP meets the certification requirements: 42 CFR 8.11(c)(3).
7. DEA registration on Form 363, $296, one-year registration period, renewed on Form 363a.
8. Complete accreditation within the provisional year, then convert to standard certification: a term not to exceed 3 years under 42 CFR 8.11(a)(3).

Note the trap at renewal: an OTP seeking certification renewal that has been granted only a one-year accreditation may receive a one-year conditional certification under 42 CFR 8.11(a)(5). If standard accreditation is not obtained inside that year, the conditional certification lapses and the Attorney General is notified that the registration should be revoked. Under 8.11(a)(6), an OTP whose certification has expired is treated as a "new" program and must apply for provisional certification again.

How long does it take?

Federal regulation sets no processing deadline for SAMHSA certification, and we could not find a published median for any stage. What the rules fix is the structure: accreditation must be applied for before provisional certification, provisional certification runs up to one year, and DEA registration cannot precede SAMHSA's determination.

We give no month count, because we could not source one. Ask your SOTA, your Accreditation Body and, in a CON state, the health planning agency for their current timelines in writing, and budget fixed cost for that whole period.

Do you need a Certificate of Need?

It depends on the state. Tennessee is one that names opioid treatment explicitly. Its State Health Plan CON standards define the category as "Non-Residential Opioid Treatment Programs or Nonresidential Substitution-based Treatment Centers for Opiate Addiction as referenced in TCA § 68-11-1607", and a letter of intent dated 15 July 2026 gives the Tennessee Health Facilities Commission notice of an intended application for a Certificate of Need for "establishment of a non-residential substitution based opioid treatment center" in Sevier County.

A worked fee example from that filing. The letter gives an estimated project cost of $726,260. The Commission's filing instructions set the initial filing fee at "$2.25 per $1,000 of the estimated project cost involved, but in no case shall the fee be less than $3,000 or more than $45,000". $726,260 at $2.25 per $1,000 is $1,634.09, which is below the minimum, so on that estimate the initial fee is the $3,000 minimum and the published government fees for year one come to $3,296 with DEA registration. The $726,260 is the applicant's own estimate and the letter gives no breakdown, so read it as one filing, not a benchmark.

We could not retrieve an authoritative, current state-by-state list of which states apply CON to outpatient OTPs, and you should not rely on a secondary one. Ask your SOTA and state health planning agency directly, in writing, before signing a lease.

How do people finance an opioid treatment program?

SBA 7(a) is available in principle. The obvious founder question is whether dispensing a Schedule II controlled substance disqualifies you. On the face of the rules, no. The current rulebook is SOP 50 10 8.1, effective 1 October 2026, which replaced SOP 50 10 8. It carries SBA's ineligibility bar at 13 CFR 120.110(h) in these words (Section A, Chapter 1, Types of Ineligible Businesses): "Businesses that are engaged in any activity that is illegal under federal, state, or local law are not eligible". The SOP's own example under that bar is marijuana, where it starts from the premise that "federal law prohibits the distribution and sale of marijuana". An OTP is in a different position: federal regulation provides for an OTP to be certified and then registered by the DEA to dispense medication for opioid use disorder (42 CFR 8.11(a)(1) and (e)(6)), and SOP 50 10 8.1 contains no OTP-specific exclusion: a search of its full text on 11 October 2026 found no occurrence of opioid, methadone, narcotic or controlled substance. Non-profit businesses are barred separately (13 CFR 120.110(a)); the full list is in our guide to SBA ineligible businesses. Lender credit policy is separate from SBA eligibility, and we could not source any data on how SBA lenders in fact treat the sector. Treat lender appetite as something to test early with named lenders rather than assume.

SOP 50 10 8.1 states that the "maximum loan amount for any one Standard 7(a) loan is $5,000,000" (Section B, Chapter 1). It treats a business as a "start-up" for equity injection purposes "if it has been in operation (i.e., generating revenue from intended operations) for 1 year or less", and, for Standard 7(a) and 7(a) Small loans, requires an equity injection of at least 10 percent of total project costs for such a business, a base it defines as "all costs required to become operational, regardless of the source of funds, except for lines of credit and 504 loans". See our guide to SBA equity injection requirements.

504 is where property classification bites. SOP 50 10 8.1's list of examples of a Limited or Special Purpose Property (Section C, Chapter 1, Borrower's Contribution) includes "Hospitals, surgery centers, urgent care centers, and other health or medical facilities". It does not name an opioid treatment program, and the SOP does not say how far "other health or medical facilities" reaches. What it does give is a definition and an open list. Appendix 3 defines a Limited or Special Purpose Property as "A limited-market property with a unique physical design, special construction materials, or a layout that restricts its utility to the use for which it was built"; the list "is not intended to be all-inclusive"; and CDCs "must address whether the Project Property is Limited or Special Purpose in their credit memorandum". Our reading is that a building fitted out as an OTP clinic falls within the health entry, so budget on that footing and ask your CDC for its conclusion in writing. Under the SOP a business with a Limited or Special Purpose Property contributes at least 15%, and "Must contribute at least 20%, if the Project involves a new business"; a new business in any other property also contributes at least 15%, and 10% is the minimum only where neither condition applies. 13 CFR 120.910(a) sets the same floors. Note that the 504 test is not the 7(a) one: 13 CFR 120.910(a)(1) keys the higher contribution to a borrower that "has operated for two years or less", not one year. Plan the extra equity from the outset.

One practical detail, and it is the opposite of what founders often assume. For all 7(a) loans, SOP 50 10 8.1 (Section B, Chapter 6, Loan Closing and Disbursement, under the heading Licenses; Chapter 5 in SOP 50 10 8) provides: "The Lender must obtain evidence from the Borrower of all licenses required to operate the business within no more than 90 days after final disbursement of the loan. The loan may not be sold into the secondary market until all required licenses are obtained." So the deadline that paragraph sets for license evidence falls after final disbursement, and what it gates is the secondary-market sale. The same chapter limits that reading. The lender must meet the required terms and conditions identified in its own credit memorandum before or at the time of disbursement. For SBA Express, Export Express and 7(a) Small loans, the conditions to be met before disbursement include "requirements identified in the loan write-up, such as standby agreements, appraisals or evaluations, business licenses, and cash/equity injections". And where the construction component of a 7(a) loan is more than $350,000, the lender must make interim and final inspections and obtain "evidence that the building, when completed, will comply with all state and local building and zoning codes, and applicable licensing and permit requirements". Do not plan a milestone-tranched draw on the assumption that SBA's license paragraph requires one; ask your lender for its disbursement conditions in writing.

What do the operating economics look like?

Here are the published reimbursement rates we could source. The "per patient, per year" column is our own annualization, not a payer-published annual figure: it assumes a full year of billed weeks or months with no gaps. All annualized figures are rounded to the nearest dollar, rounding half up.

Read those two payers against each other: carefully. Vermont's monthly rate works out at about $106.36 per patient per week; Medicare pays $277.29 for its weekly methadone bundle. Annualized, that is $14,419 against $5,531 per patient, a ratio of about 2.6 to 1, falling to about 1.9 to 1 against Vermont's $7,593 with-health-home tier. Two warnings before you use that ratio. First, the two rates are not shown to be like-for-like. CMS describes G2067 as a "weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed". The Vermont rate sheet prints H0020 with a unit of one month and two tiers, without and with health home services, and does not define what the monthly rate covers. Treat the comparison as a contrast between two payers' rate levels, not as two prices for one identical product. Second, Medicare rates shown are national and unadjusted, and Medicaid rates are set state by state, so pull your own state's schedule rather than using Vermont's as a proxy.

Add-ons matter at the margin: for CY 2026 Medicare pays $234.59 for intake (G2076), $151.93 per periodic assessment (G2077), $44.41 per additional 7-day methadone take-home supply (G2078) and $36.97 per additional 30 minutes of counseling (G2080). CMS states that for CY 2026 the non-drug component was updated by the Medicare Economic Index, "which reflects an increase of 2.7% for CY 2026."

Scale, and what it does and does not tell you. SAMHSA's 2024 final rule records that "As of June 2023, there are over 2,000 OTPs in the United States, providing care to over 650,000 patients" (89 FR 7529, in the final rule beginning at 89 FR 7528). Dividing one open-ended lower bound by another does not produce an average census, and we will not present it as one: the direction of the error is unknowable. Use it only as an order-of-magnitude sense of the sector, and build your census from your own catchment analysis.

Breakeven census. Breakeven is annual fixed operating cost divided by annual revenue per patient, so it needs no assumption about the national average. Illustrating the mechanics only, at $1.5M of annual operating cost, an assumption you must replace with your own quotes; it is not a sourced figure, you would need about 104 patients at Medicare methadone rates, about 198 at Vermont's with-health-home rate, or about 271 at Vermont's no-health-home rate. That gap is the whole business case. These are single-payer illustrations: your own breakeven depends on your actual payer mix and your own state's rates.

What makes these projects fail?

These follow from the rules and figures above. They are our reading, not a surveyed ranking:

• Sequencing the gates wrong, signing a lease before confirming CON status or SOTA support, then carrying rent through an approval that never arrives.
• Underfunding the carry, capitalizing the build and not the payroll behind it.
• Assuming Medicare-like rates in a low-rate Medicaid state: a model built on $277 a week that in practice collects the equivalent of about $106 fails at any census.
• Letting accreditation slip past the provisional year, which under 42 CFR 8.11 costs you certification and, in the conditional-certification case at 8.11(a)(5), triggers notice that your DEA registration should be revoked.
• Treating security as an equipment line, then discovering the 21 CFR 1301.72 vault spec after the build-out is designed.
• Siting without zoning and community groundwork. We are not lawyers and give no view on your case; take land-use advice in your own state before you commit to a site.

Is this actually viable for you? Sometimes the answer is no.

Three tests. The first two are our own opinion, not anyone's published standard.

Is the pre-revenue carry funded in full, separate from the build budget? We could not find a published figure for how long the gate chain takes, so we give no month count: use the timelines your SOTA, your Accreditation Body and any CON agency give you in writing. Our opinion is that a project with the build funded and the carry unfunded should not proceed.

What does your state Medicaid program pay for H0020 or its equivalent? Pull the fee schedule before anything else. If your state pays near the low end and your catchment is predominantly Medicaid, the arithmetic may not close at any realistic census, and operational discipline does not fix a rate problem.

Do you have a program sponsor and medical director committed in writing? 42 CFR 8.12(b)(1) provides that "At a minimum, each OTP shall formally designate a program sponsor and medical director", and 8.11(e)(5) requires notice to SAMHSA in writing within 3 weeks of any replacement or other change in the status of either. Without named clinical leadership you cannot file a credible SMA-162.

If you cannot clear all three, the better route is often a medication unit under an existing certified OTP. Under 42 CFR 8.11(h)(1), "Certified OTPs may establish medication units that are authorized to dispense MOUD. Before establishing a medication unit, a certified OTP must notify the Secretary by submitting form SMA-162." Medication units include both mobile and brick-and-mortar facilities. That route requires a certified OTP partner, but it avoids certifying a new program from scratch.

Frequently asked questions

Does SAMHSA charge a fee to certify an OTP?

No fee is prescribed. 42 CFR 8.11(b) sets out what Form SMA-162 must contain, accreditation status, organizational structure, the persons responsible for the OTP, addresses, funding sources, a compliance statement and the program sponsor's signature, and the section establishes no certification fee. Your paid federal cost is DEA registration at $296, plus whatever your accrediting body quotes you.

How much is DEA registration for a methadone clinic?

$296 on DEA Form 363, with a one-year registration period, under 21 CFR 1301.13(e)(1)(viii). This differs from a dispensing practitioner or hospital/clinic registration, which is $888 for a three-year period under 21 CFR 1301.13(e)(1)(iv). An OTP registers in the Narcotic Treatment Program category and renews on Form 363a.

Can I open before accreditation is complete?

Yes. 42 CFR 8.11(d) allows provisional certification for up to one year for a new OTP that has already applied to an Accreditation Body. You must tell SAMHSA which body, the date you applied, the dates of any surveys and your expected schedule for completing accreditation, and still finish accreditation inside that window.

Is an OTP eligible for an SBA 7(a) loan?

SOP 50 10 8.1 does not name opioid treatment programs and has no exclusion specific to them; a non-profit OTP is ineligible under 13 CFR 120.110(a). The maximum for any one Standard 7(a) loan is $5,000,000. A start-up in operation one year or less needs an equity injection of at least 10 percent of total project costs on Standard 7(a) and 7(a) Small loans. Lender credit policy is separate.

Is a clinic building a special-purpose property for SBA purposes?

Not by name. SOP 50 10 8.1's examples of a Limited or Special Purpose Property include "Hospitals, surgery centers, urgent care centers, and other health or medical facilities"; whether an OTP clinic falls within those words is for the CDC's credit memorandum. Under 504, a business with such a property contributes at least 15%, or 20% if the Project involves a new business (13 CFR 120.910).

Can I run a mobile methadone unit?

Yes, with DEA approval. Under 21 CFR 1301.13(e)(4) an NTP must notify its local DEA office in writing and receive explicit written approval before operating a mobile NTP, which "may only operate in the same State in which the NTP is registered". Under 21 CFR 1301.72(e) the conveyance needs a conforming safe and alarm and must return to the registered location after each day's operation unless DEA grants an exception.

What a lender will ask you for

CON approval or written confirmation that CON does not apply; your state license application and SOTA correspondence; the accreditation application with survey dates; your filed Form SMA-162 and provisional certification; DEA Form 363; a named program sponsor and medical director committed in writing; your state Medicaid fee schedule with the codes you will bill; a monthly cash-flow model from lease signature to breakeven with the carry fully funded; and a site plan showing the DEA storage build.

Verify before you commit capital. Fee schedules, reimbursement rates, accreditation pricing and CON rules all change, and one source on this page, the Joint Commission's pricing page, had to be read from an archived capture because the live page refuses automated retrieval. Confirm current requirements directly with SAMHSA's Division of Pharmacologic Therapies, your State Opioid Treatment Authority, the DEA Diversion Control Division, your state Medicaid agency, your state health planning or CON agency, and your accrediting body before spending money. Nothing here is legal, clinical or financial advice.

Business Plan Firm is the US practice of Avvale, a London consultancy. We have written $1B+ in funding documents for 500+ businesses across 30+ countries, including Shark Tank and Dragons' Den clients. If you want the licensing timeline, payer-mix model and lender package built for your state, we can help.

Book a free 30-minute call

Written by Muhammad Tayyab Shabbir, UCL, published textbook author. Sources retrieved 22 August 2026. Federal regulations were read from the eCFR versioner API (/api/versioner/v1/full/2026-08-20/), which serves the title text directly; the eCFR web renderer redirects automated requests to an interstitial. The Joint Commission's pricing page returned HTTP 403 to direct retrieval and was read from an Internet Archive capture, dated in the table above. The SBA rules were checked again on 11 October 2026 against SOP 50 10 8.1 (effective 1 October 2026) and the current text of 13 CFR 120.110 and 120.910. Read on 11 October 2026 from the live files: Tennessee Rule 0720-10, the Commission's filing instructions, OTP standards and the letter of intent of 15 July 2026; the CMS OTP payment rates; the Vermont rate sheet; and 42 CFR 8.11 and 21 CFR 1301.13 and 1301.72. The remaining sources are as retrieved on 22 August 2026.

Related cost guides